ArticleSubstance abuse2019
Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs.
Article in Substance abuse, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.Contemporary clinical trials · 2023Trial
- Aligning Efforts to Boost Medications for Opioid Use Disorder and Pre-Exposure Prophylaxis for HIV.Journal of general internal medicine · 2026Article
- PrEP Use Likelihood Among People Who Use Opioid Drugs: Understanding Clinical Correlates Along the Opioid Use Disorder Treatment Cascade.AIDS and behavior · 2026Article
- Article
- Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA.Addiction science & clinical practice · 2024Article
- Interventions for HIV prevention and treatment among people of Haitian descent: a scoping review.BMJ open · 2024Article
- Safe Injection Self-Efficacy is Associated with HCV and HIV Seropositivity Among People Who Inject Drugs in the San Diego-Tijuana Border Region.AIDS and behavior · 2024Article
- PrEP facilitators and barriers in substance use bridge clinics for women who engage in sex work and who use drugs.Addiction science & clinical practice · 2024Article
- Safe Injection Self-Efficacy is associated with HCV and HIV seropositivity among people who inject drugs in the San Diego-Tijuana border region.medRxiv : the preprint server for health sciences · 2024Article
- Willingness to use and distribute HIV self-testing kits among people who inject drugs in the San Diego-Tijuana border region.Harm reduction journal · 2024Article
- Interrogating perceived relevance and feasibility of HIV pre-exposure prophylaxis: A novel model of PrEP acceptability among cisgender women who inject drugs.SSM. Qualitative research in health · 2023Article
- Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.Journal of general internal medicine · 2023Article
- Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice.Substance abuse · 2022Review
- Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California.AIDS patient care and STDs · 2022Article
- Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.Journal of general internal medicine · 2021Review
- A collision of crises: Addressing an HIV outbreak among people who inject drugs in the midst of COVID-19.Journal of substance abuse treatment · 2021Article
- Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments.Infectious disease clinics of North America · 2020Review
- Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs.Infectious disease clinics of North America · 2020Review
- Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States.Journal of the International AIDS Society · 2020Article
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The opioid and polysubstance epidemics could drive a surge in new HIV infections among people who inject drugs (PWID). Longstanding strategies to reduce HIV incidence, including syringe service programs, condom distribution, medications for opioid use disorder, and low-barrier HIV testing and treatment have not been adequate to eliminate transmission in this population. Although HIV pre-exposure prophylaxis (PrEP) is an evidence-based intervention that reduces HIV incidence among PWID, uptake in PWID has lagged due to limited PrEP knowledge, discrepancies between perceived and actual HIV risk, stigma, and structural barriers to adherence including homelessness and incarceration. In our efforts to deploy PrEP to PWID in our low-barrier substance use disorder bridge clinic, we have encountered another barrier: the HIV testing window period. We discuss challenges in delivering HIV exposure prophylaxis to the highest risk PWID, our current approach, and the need for more data to guide best practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.